Lannett Company, Inc. (AMEX:LCI) today said it will continue to market its Digoxin Tablets and that the company’s Digoxin product is not subject to the recent FDA announced recall of Digitek®, the brand version of Digoxin Tablets. Lannett’s Digoxin product is manufactured by Jerome Stevens Pharmaceutical and has never been subject to recall.
“We are working with the FDA to ensure that there will not be a disruption in the supply of this important medication,” said Arthur Bedrosian president and chief executive officer of Lannett. “Our supplier has begun ramping up production of Digoxin Tablets, 0.125 mg and 0.25 mg, and we expect to meet the anticipated demand.”
Digoxin is indicated for the treatment of mild to moderate heart failure as well as for the control of ventricular response rate in patients with chronic atrial fibrillation.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at www.lannett.com.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, projected sales estimates, developing and filing product candidates, distribution and commercialization of products, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.
Contacts:
Robert Jaffe/Evan Pondel, 310-279-5980
